MedTrace Logo

Sugammadex Dosing: Anaesthesiologist Clinical Perception Versus Quantitative Monitoring

NCT04762420 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2021-02-21

No results posted yet for this study

Summary

Many clinicians continue to rely on subjective evaluation in making decisions about the adequacy of neuromuscular function before tracheal extubation rather than using quantitative monitoring. The aim was to compare the sugammadex dose as suggested by senior anaesthesiologists (SSD) based on clinical experience versus the dose determined by quantitative monitoring (QSD) to determine if the subjective dose was appropriate.

Conditions

  • Neuromuscular Blockade
  • Anesthesia
  • TOF
  • Curarization, Postoperative Residual

Interventions

OTHER

Dose of sugammadex according to SSD and QSD

At the time of pharmacologic reversal of the NMB, both the SSD and QSD, according to portuguese guidelines on the management of the NMB, were recorded. The QSD was then administered to the patient. The SSD was considered appropriate if it was within 10% of the recommended dose for the given depth of NMB, as measured by TOFscan® monitor. The results were analyzed descriptively.

Sponsors & Collaborators

  • Hospital do Divino Espírito Santo de Ponta Delgada

    lead OTHER

Principal Investigators

  • Paulo Frias, MD · Hospital do Divino Espírito Santo de Ponta Delgada

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04762420 on ClinicalTrials.gov